This content is machine translated Multiple sclerosis Avoiding the nocebo trap with natalizumab biosimilars Monoclonal antibodies such as natalizumab are indispensable for multiple sclerosis therapy. A first recently approved biosimilar is clinically equivalent, as studies have shown. Nevertheless, reservations are widespread in practice. Patients...…
View Post 2 min This content is machine translated Biosimilars Exchange with reference preparations possible without problems Biosimilars are inexpensive imitation drugs of expensive biological drugs. Now, Swissmedic has confirmed that the two types of drugs are comparable in terms of efficacy and safety. The Federal Office…
